Of importance, therapeutically targeting eIF4E with Pep8 was found to abrogate the RBM38-eIF4E complex, induce wild-type p53 expression, and sensitize cancer cells to doxorubicin, in vitro and in vivo (7). Here, TP53 is linked to cancer.